Effect of Osteoporosis Treatment Agents on the Cortical Bone Osteocyte Microenvironment in Adult Estrogen-deficient, Osteopenic Rats

Overview

Journal Bone Rep

Date 2018 Jun 30

PMID 29955630

Citations 8

Authors

Amber Rath Stern

Xiaomei Yao

Yong Wang

Amanuel Berhe

Mark Dallas

Mark L Johnson

Wei Yao

Donald B Kimmel

Nancy E Lane

Affiliations

Soon will be listed here.

Abstract

Though osteoporosis is a significant cause of disability worldwide, treatment with pharmacologic agents decreases risk of fragility fracture. Though these treatments act through the bone remodeling system to improve bone mass, it is unclear if they alter the response of bone to mechanical loading at the level of the osteocyte. This pre-clinical study determined the relationship between microstructural bone tissue properties and osteocyte lacunar size and density to strain around osteocytes with standard osteoporosis treatment or sequential therapies. Six-month-old female ovariectomized (OVX) Sprague-Dawley rats were cycled through various sequences of pharmacological treatments [alendronate (Aln), raloxifene (Ral) and human parathyroid hormone-1,34 (PTH)] for three month intervals, over nine months. Linear nanoindentation mapping was used to determine Young's modulus in perilacunar and bone matrix regions around cortical bone osteocyte lacunae. Measurements of lacunar diameter and density were completed. Treatment-related differences in Young's modulus in the perilacunar and bone matrix regions were not observed. We confirmed previous data that showed that the bone matrix region was stiffer than the perilacunar matrix region. Whole bone material properties were correlated to perilacunar matrix stiffness. Finite element models predicted a range of mechanical strain amplification factors estimated at the osteocyte across treatment groups. In summary, though the perilacunar matrix near cortical osteocyte lacuna is not as stiff as bone matrix further away, osteoporosis treatment agents do not affect the stiffness of bone tissue near osteocyte lacunae.

Citing Articles

Contributions of Resin Cast Etching to Visualising the Osteocyte Lacuno-Canalicular Network Architecture in Bone Biology and Tissue Engineering.

Sato M, Shah F Calcif Tissue Int. 2023; 112(5):525-542.

PMID: 36611094 PMC: 10106349. DOI: 10.1007/s00223-022-01058-9.

The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches.

Lugnier C Int J Mol Sci. 2022; 23(18).

PMID: 36142518 PMC: 9502408. DOI: 10.3390/ijms231810616.

Perilacunar bone tissue exhibits sub-micrometer modulus gradation which depends on the recency of osteocyte bone formation in both young adult and early-old-age female C57Bl/6 mice.

Rux C, Vahidi G, Darabi A, Cox L, Heveran C Bone. 2022; 157:116327.

PMID: 35026452 PMC: 8858864. DOI: 10.1016/j.bone.2022.116327.

Osteocyte Wnt/β-catenin pathway activation upon mechanical loading is altered in ovariectomized mice.

Jackson E, Lara-Castillo N, Akhter M, Dallas M, Scott J, Ganesh T Bone Rep. 2021; 15:101129.

PMID: 34584905 PMC: 8455641. DOI: 10.1016/j.bonr.2021.101129.

Control of Bone Matrix Properties by Osteocytes.

Creecy A, Damrath J, Wallace J Front Endocrinol (Lausanne). 2021; 11:578477.

PMID: 33537002 PMC: 7848033. DOI: 10.3389/fendo.2020.578477.

References

Qing H, Ardeshirpour L, Divieti Pajevic P, Dusevich V, Jahn K, Kato S . Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res. 2012; 27(5):1018-29. PMC: 3770147. DOI: 10.1002/jbmr.1567. View

Nowak B, Matuszewska A, Filipiak J, Nikodem A, Merwid-Lad A, Piesniewska M . The Negative Impact of Selective Activation of Retinoic Acid Receptors on Bone Metabolism and Bone Mechanical Properties in Rats. Adv Clin Exp Med. 2016; 25(2):213-8. DOI: 10.17219/acem/41860. View

Roberts M, Santner T, Hart R . Local bone formation due to combined mechanical loading and intermittent hPTH-(1-34) treatment and its correlation to mechanical signal distributions. J Biomech. 2009; 42(15):2431-8. DOI: 10.1016/j.jbiomech.2009.08.030. View

Lu Y, Yuan B, Qin C, Cao Z, Xie Y, Dallas S . The biological function of DMP-1 in osteocyte maturation is mediated by its 57-kDa C-terminal fragment. J Bone Miner Res. 2010; 26(2):331-40. PMC: 3179348. DOI: 10.1002/jbmr.226. View

Gamsjaeger S, Mendelsohn R, Boskey A, Gourion-Arsiquaud S, Klaushofer K, Paschalis E . Vibrational spectroscopic imaging for the evaluation of matrix and mineral chemistry. Curr Osteoporos Rep. 2014; 12(4):454-64. PMC: 4638121. DOI: 10.1007/s11914-014-0238-8. View

Norimatsu H, Wiel C, TALMAGE R . Electron microscopic study of the effects of calcitonin on bone cells and their extracellular milieu. Clin Orthop Relat Res. 1979; (139):250-8. View

Takeda S, Sakai S, Tanaka K, Tomizawa H, Serizawa K, Yogo K . Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats. Calcif Tissue Int. 2017; 101(1):65-74. PMC: 5486915. DOI: 10.1007/s00223-017-0255-6. View

Parfitt A . The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption--bone flow theory. Clin Orthop Relat Res. 1977; (127):236-47. View

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

10.

Turner C, Takano Y, Owan I . Aging changes mechanical loading thresholds for bone formation in rats. J Bone Miner Res. 1995; 10(10):1544-9. DOI: 10.1002/jbmr.5650101016. View

11.

Wronski T, Yen C, Qi H, DANN L . Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology. 1993; 132(2):823-31. DOI: 10.1210/endo.132.2.8425497. View

12.

Schneider P, Meier M, Wepf R, Muller R . Towards quantitative 3D imaging of the osteocyte lacuno-canalicular network. Bone. 2010; 47(5):848-58. DOI: 10.1016/j.bone.2010.07.026. View

13.

Black D, Arden N, Palermo L, Pearson J, Cummings S . Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1999; 14(5):821-8. DOI: 10.1359/jbmr.1999.14.5.821. View

14.

Amugongo S, Yao W, Jia J, Dai W, Lay Y, Jiang L . Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats. Bone. 2014; 67:257-68. PMC: 4157684. DOI: 10.1016/j.bone.2014.04.033. View

15.

Seedor J, Quartuccio H, Thompson D . The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res. 1991; 6(4):339-46. DOI: 10.1002/jbmr.5650060405. View

16.

Ross P, Davis J, Epstein R, Wasnich R . Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991; 114(11):919-23. DOI: 10.7326/0003-4819-114-11-919. View

17.

Matthews J, Wiel C, TALMAGE R . Bone lining cells and the bone fluid compartment, an ultrastructural study. Adv Exp Med Biol. 1978; 103:451-8. DOI: 10.1007/978-1-4684-7758-0_46. View

18.

Shahnazari M, Yao W, Dai W, Wang B, Ionova-Martin S, Ritchie R . Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats. Bone. 2009; 46(5):1267-74. PMC: 3003226. DOI: 10.1016/j.bone.2009.11.019. View

19.

Xu C, Reed R, Gorski J, Wang Y, Walker M . The Distribution of Carbonate in Enamel and its Correlation with Structure and Mechanical Properties. J Mater Sci. 2014; 47(23):8035-8043. PMC: 4160314. DOI: 10.1007/s10853-012-6693-7. View

20.

Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333(22):1437-43. DOI: 10.1056/NEJM199511303332201. View